Pfizer

(

PFE

) pushed the Drugs industry lower today making it today's featured Drugs loser. The industry as a whole closed the day down 0.9%. By the end of trading, Pfizer fell 17 cents (-0.8%) to $22.37 on average volume. Throughout the day, 33.9 million shares of Pfizer exchanged hands as compared to its average daily volume of 37.9 million shares. The stock ranged in price between $22.22-$22.68 after having opened the day at $22.48 as compared to the previous trading day's close of $22.54. Other company's within the Drugs industry that declined today were:

Biosante Pharmaceuticals

(

BPAX

), down 13%,

NuPathe

(

PATH

), down 12.9%,

Chelsea Therapeutics International

(

CHTP

), down 12%, and

China Botanic Pharmaceutical

(

CBP

), down 10%.

Pfizer Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and sale of medicines for people and animals worldwide. Pfizer has a market cap of $168.93 billion and is part of the

health care

sector. The company has a P/E ratio of 21.1, above the average drugs industry P/E ratio of 18 and above the S&P 500 P/E ratio of 17.7. Shares are up 4.2% year to date as of the close of trading on Monday. Currently there are 15 analysts that rate Pfizer a buy, no analysts rate it a sell, and two rate it a hold.

TheStreet Ratings rates Pfizer as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, expanding profit margins, notable return on equity and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front,

Amyris

(

AMRS

), up 16.4%,

Rosetta Genomics

(

ROSG

), up 8.3%,

China Pharma

(

CPHI

), up 8.2%, and

Galectin Therapeutics

(

GALT

), up 6.1%, were all gainers within the drugs industry with

Vertex Pharmaceuticals

(

VRTX

) being today's featured drugs industry winner.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null